Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001GlobeNewsWire • 12/23/19
Once Shunned For Marketing Approval, Golodirsen Is Now A Major Win For SareptaSeeking Alpha • 12/14/19
Sarepta Therapeutics News: SRPT Stock Skyrockets 36% on FDA Approval of Muscular Dystrophy DrugInvestorPlace • 12/13/19
Sarepta Therapeutics Announces $250 Million of Non-Dilutive Senior Secured Loan FinancingGlobeNewsWire • 12/13/19
Sarepta Therapeutics Announces FDA Approval of VYONDYS 53™ (golodirsen) Injection for the Treatment of Duchenne Muscular Dystrophy (DMD) in Patients Amenable to Skipping Exon 53GlobeNewsWire • 12/12/19
Why Is Sarepta Therapeutics (SRPT) Up 17.2% Since Last Earnings Report?Zacks Investment Research • 12/07/19
Sarepta Therapeutics Will Have A Hard Time Getting Any New DMD Drugs Past FDASeeking Alpha • 11/18/19